Free

Event Information

Share this event

Date and Time

Location

Location

Renaissance Los Angeles Airport Hotel

9620 Airport Boulevard

Los Angeles, CA 90045

View Map

Event description

Description

The California Technology Assesment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), will hold a public meeting on June 14, 2018 to consider the comparative clinical effectiveness and value of CGRP inhibitors for migraine.

Migraine is a common, recurrent headache disorder that affects approximately 18% of women and 6% of men in the United States (US). Migraine is among the top ten causes of years lived with disability in the US. When a person experiences a migraine, she or he may feel moderate-to-severe pain and other symptoms (e.g., nausea, vomiting, or sensitivity to light or to sound), have a reduced ability to function, or require bed rest. Despite its high prevalence and impairment, migraine is often not recognized or effectively treated.

ICER will be evaluating the following CGRP inhibitors: Erenumab (Amgen/Novartis), Fremanezumab (Teva), and Galcanezumab (Eli Lilly) for the treatment of migraines.

A list of key dates for stakeholder engagement opportunities and other important information associated with the review of CAR-T therapies can be found on ICER's website at https://icer-review.org/topic/migraines/.

Share with friends

Date and Time

Location

Renaissance Los Angeles Airport Hotel

9620 Airport Boulevard

Los Angeles, CA 90045

View Map

Save This Event

Event Saved